Systematic Review : Cost-Effectiveness of Influenza Vaccination and Comparison Cost-Effectiveness between 3 and 4 Strain Vaccine in 2013-2017
Article Sidebar
Published:
Jun 7, 2019
Keywords:
influenza vaccination cost-effectiveness
Main Article Content
Abstract
Objective : The aim of this study was to systematically review published studies that evaluated the
cost-effectiveness of influenza vaccination in preventing influenza and its complications.
Material and method : From the review of a total of 25 studies on the influenza vaccine and studies comparing the efficacies of trivalent and quadrivalent influenza vaccines.
Results : Ten studies, most have found the influenza vaccine to be effective in reducing hospitalization costs both at the individual and societal level.
Conclusion : Quadrivalent influenza vaccine has been more effectiveness than trivalent vaccine in disease prevention and control. In the context of constrain recourse, quadrivalent influenza vaccine is the vaccine of choice for prevention and control influenza out-break.
Article Details
Section
Original Articles
บทความที่ได้รับการตีพิมพฺเป็นลิขสิทธิ์ของวารสาร
References
1. Health De Influenza. The Green Book. Chapter 19 2012; Available from: https://www.wp.dh.gov.uk/
immunisation/files/2012/07/Green.
2. Pitman RJ. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007;
54(6):530-8.
3. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28 Suppl 4:D45-53.
4. Irving SA. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a
defined population over four seasons: 2004-2005 through 2007-2008. Influenza Other Respir Viruses 2012; 6(1):37-43.
5. Fields BN, Knipe DM, Howley PM, Fields virology. 2013, Philadelphia: Wolters Kluwer Health/Lippincott Williams
& Wilkins.
6. Thompson WW. Estimates of US influenza-associated deaths made using four different methods. Influenza Other
Respir Viruses 2009;3(1):37-49.
7. Zhou, H. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008.
Clin Infect Dis, 2012;54(10):1427-36.
8. Galvani AP, Reluga TC, Chapman GB. Longstanding influenza vaccination policy is in accord with individual
self-interest but not with the utilitarian optimum. Proc Natl Acad Sci U S A, 2007;104(13):5692-7.
9. Wu BF, Fu F, Wang L. Imperfect Vaccine Aggravates the Long-Standing Dilemma of Voluntary Vaccination. PLoS
ONE 2011;6(6):e20577.
10. Plotkin S. Herd immunity: a rough guide. 2001;Vol. 52:911-916.
11. Myers LB, Goodwin R. Determinants of adults’ intention to vaccinate against pandemic swine flu. BMC Public
Health 2011;11(1):15.
12. Eastwood K. Acceptance of pandemic (H1N1) 2009 influenza vaccination by the Australian public. Med J Aust,
2010;192(1):33-6.
13. Liao Q. Factors affecting intention to receive and self-reported receipt of 2009 pandemic (H1N1) vaccine in Hong
Kong: a longitudinal study. PLoS One 2011;6(3):e17713.
14. Streefland PH. Public doubts about vaccination safety and resistance against vaccination. Health Policy
2001;55(3):159-72.
15. Francois, G., et al., Vaccine safety controversies and the future of vaccination programs. Pediatr Infect Dis J
2005;24(11):953-61.
16. Lau, J.T.F., et al., Acceptability of A/H1N1 vaccination during pandemic phase of influenza A/H1N1 in Hong
Kong: population based cross sectional survey. BMJ 2009;339-2.
17. Ambrose, C.S. and M.J. Levin, The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother
2012;8(1):81-8.
18. Skowronski DM. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel
surveillance network in Canada, 2006-2007. J Infect Dis 2009;199(2):168-79.
19. Beran J.Challenge of conducting a placebocontrolled randomized efficacy study for influenza vaccine in a season
with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009;9:2-5.
20. Skowronski, D.M., et al., Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel
physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine
2007;25(15):2842-51.
21. Frey S. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy
adults. Clin Infect Dis 2010;51(9):997-1004.
22. Belongia EA. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and
final results. Vaccine 2011;29(38):6558-63.
23. Heinonen S. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational
cohort study. Lancet Infect Dis 2011;11(1):23-9.
24. Janjua NZ. Estimates of influenza vaccine effectiveness for 2007-2008 from Canada’s sentinel surveillance system:
cross-protection against major and minor variants. J Infect Dis 2012;205(12):1858-68.
25. Zwahlen M. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation, 2nd Ed. Haddix A,
Teutsch SM, Corso PS. Oxford: Oxford University Press 2003.264-70.
26. Szucs T. Cost-benefits of vaccination programmes. Vaccine 2000;18 Suppl 1:S49-51.
27. Pitman RJ, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales:
Results from a dynamic transmission model. Vaccine 2013;31(6):927-42.
28. Chen SC, Liao CM. Cost-effectiveness of influenza control measures: a dynamic transmission model-based
analysis. Epidemiol Infect 2013;141(12):2581-94.
29. Wang IK. Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study. Vaccine
2013;31(4):718-24.
30. Newall AT. Understanding the cost-effectiveness of influenza vaccination in children: methodological choices and
seasonal variability. Pharmacoeconomics 2013;31(8):693-702.
31. Kelso JK, Halder N, Milne GL. Vaccination strategies for future influenza pandemics: a severity-based cost
effectiveness analysis. BMC Infect Dis 2013;13:81-5.
32. Skene KJ. A marginal benefit approach for vaccinating influenza “superspreaders”. Med Decis Making
2014;34(4):536-49.
33. Halder N, Kelso JK, Milne GJ. A model-based economic analysis of pre-pandemic influenza vaccination cost-
effectiveness. BMC Infectious Diseases 2014;14(1):266-70.
34. Zhou L. Cost-Effectiveness of Alternative Strategies for Annual Influenza Vaccination among
Children Aged 6 Months to 14 Years in Four Provinces in China. PLOS ONE 2014; 9(1):e87590.
35. Yamin D, Balicer RD, Galvani AP. Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.
Vaccine 2014;32(33):4198-205.
36. Gregg M. Economic evaluation of an influenza immunization strategy of healthy children. Int J Technol Assess
Health Care 2014;30(4):394-9.
37. Newall AT, Dehollain JP. The cost-effectiveness of influenza vaccination in elderly Australians: an exploratory
analysis of the vaccine efficacy required. Vaccine 2014;32(12):1323-5.
38. Yoo BK. Cost effectiveness analysis of Year 2 of an elementary school-located influenza vaccination program–
Results from a randomized controlled trial. BMC Health Services Research 2015;15:511-20.
39. Chit A. Expected cost effectiveness of highdose trivalent influenza vaccine in US seniors. Vaccine
2015;33(5):734-41.
40. Baguelin M. Extending the elderly- and riskgroup programme of vaccination against seasonal influenza in England
and Wales: a cost-effectiveness study. BMC Med 2015;13:236-40.
41. Lee BY. Quantifying the economic value and quality of life impact of earlier influenza vaccination. Med Care
2015;53(3):218-29.
42. Meeyai A. Seasonal Influenza Vaccination for Children in Thailand: A Cost-Effectiveness Analysis. PLOS Medicine
2015;12(5):e1001829.
43. Thorrington D, Jit M, Eames K. Targeted vaccination in healthy school children - Can primary school vaccination
alone control influenza? Vaccine 2015;33(41):5415-24.
44. Smith KJ. Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S. Am J Prev Med
2016;50(5):600-8.
45. Akin L. Cost-Effectiveness of Increasing Influenza Vaccination Coverage in Adults with Type 2 Diabetes in
Turkey. PLoS One 2016;11(6):e0157657.
46. Xu J. Cost-effectiveness of seasonal inactivated influenza vaccination among pregnant women. Vaccine
2016;34(27):3149-55.
47. Becker DL. High-dose inactivated influenza vaccine is associated with cost savings and better outcomes
compared to standard-dose inactivated influenza vaccine in Canadian seniors. Hum Vaccin Immunother
2016;12(12):3036-42.
48. Thorrington D. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England. BMC Med
2017;15(1):166-70.
49. Kittikraisak W. Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ?60
months of age. PLoS ONE 2017;12(8):e0183391.
50. Orenstein EW. Cost-effectiveness of maternal influenza immunization in Bamako, Mali: A decision analysis. PLoS
One 2017;12(2):e0171499.
51. Hodgson D. Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in
England and Wales: a modelling and cost-effectiveness analysis. The Lancet Public Health;2(2):e74-e81.
52. You, J.H., W.K. Ming, and P.K. Chan, Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent
influenza vaccine for elderly in Hong Kong. BMC Infect Dis, 2014.14:p. 618.
53. Blommaert A. Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and
persons with underlying illnesses in Belgium. Vaccine 2014; 32(46):6075-83.
54. Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent
influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One
2014;9(6):e98437.
55. Thommes EW. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention:
a dynamic modeling study of Canada and the United Kingdom. BMC Infectious Diseases 2015;15(1):465-70.
56. You JH, Ming WK, Chan PK. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision
analysis. Hum Vaccin Immunother 2015;11(3):564-71.
57. de Boer PT. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States. Value
Health 2016;19(8):964-75.
58. Dolk C. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based
Dynamic Transmission Model. Pharmacoeconomics 2016;34(12):1299-308.
59. Nagy L. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in
Finland. Pharmacoeconomics 2016;34:939-51.
60. Uhart M. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza
vaccines compared to trivalent influenza vaccines in Europe. Hum Vaccin Immunother 2016;12(9):2259-68.
61. Raviotta JM. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults. J
Am Geriatr Soc 2016;64(10):2126-31.
immunisation/files/2012/07/Green.
2. Pitman RJ. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007;
54(6):530-8.
3. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28 Suppl 4:D45-53.
4. Irving SA. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a
defined population over four seasons: 2004-2005 through 2007-2008. Influenza Other Respir Viruses 2012; 6(1):37-43.
5. Fields BN, Knipe DM, Howley PM, Fields virology. 2013, Philadelphia: Wolters Kluwer Health/Lippincott Williams
& Wilkins.
6. Thompson WW. Estimates of US influenza-associated deaths made using four different methods. Influenza Other
Respir Viruses 2009;3(1):37-49.
7. Zhou, H. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008.
Clin Infect Dis, 2012;54(10):1427-36.
8. Galvani AP, Reluga TC, Chapman GB. Longstanding influenza vaccination policy is in accord with individual
self-interest but not with the utilitarian optimum. Proc Natl Acad Sci U S A, 2007;104(13):5692-7.
9. Wu BF, Fu F, Wang L. Imperfect Vaccine Aggravates the Long-Standing Dilemma of Voluntary Vaccination. PLoS
ONE 2011;6(6):e20577.
10. Plotkin S. Herd immunity: a rough guide. 2001;Vol. 52:911-916.
11. Myers LB, Goodwin R. Determinants of adults’ intention to vaccinate against pandemic swine flu. BMC Public
Health 2011;11(1):15.
12. Eastwood K. Acceptance of pandemic (H1N1) 2009 influenza vaccination by the Australian public. Med J Aust,
2010;192(1):33-6.
13. Liao Q. Factors affecting intention to receive and self-reported receipt of 2009 pandemic (H1N1) vaccine in Hong
Kong: a longitudinal study. PLoS One 2011;6(3):e17713.
14. Streefland PH. Public doubts about vaccination safety and resistance against vaccination. Health Policy
2001;55(3):159-72.
15. Francois, G., et al., Vaccine safety controversies and the future of vaccination programs. Pediatr Infect Dis J
2005;24(11):953-61.
16. Lau, J.T.F., et al., Acceptability of A/H1N1 vaccination during pandemic phase of influenza A/H1N1 in Hong
Kong: population based cross sectional survey. BMJ 2009;339-2.
17. Ambrose, C.S. and M.J. Levin, The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother
2012;8(1):81-8.
18. Skowronski DM. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel
surveillance network in Canada, 2006-2007. J Infect Dis 2009;199(2):168-79.
19. Beran J.Challenge of conducting a placebocontrolled randomized efficacy study for influenza vaccine in a season
with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009;9:2-5.
20. Skowronski, D.M., et al., Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel
physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine
2007;25(15):2842-51.
21. Frey S. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy
adults. Clin Infect Dis 2010;51(9):997-1004.
22. Belongia EA. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and
final results. Vaccine 2011;29(38):6558-63.
23. Heinonen S. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational
cohort study. Lancet Infect Dis 2011;11(1):23-9.
24. Janjua NZ. Estimates of influenza vaccine effectiveness for 2007-2008 from Canada’s sentinel surveillance system:
cross-protection against major and minor variants. J Infect Dis 2012;205(12):1858-68.
25. Zwahlen M. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation, 2nd Ed. Haddix A,
Teutsch SM, Corso PS. Oxford: Oxford University Press 2003.264-70.
26. Szucs T. Cost-benefits of vaccination programmes. Vaccine 2000;18 Suppl 1:S49-51.
27. Pitman RJ, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales:
Results from a dynamic transmission model. Vaccine 2013;31(6):927-42.
28. Chen SC, Liao CM. Cost-effectiveness of influenza control measures: a dynamic transmission model-based
analysis. Epidemiol Infect 2013;141(12):2581-94.
29. Wang IK. Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study. Vaccine
2013;31(4):718-24.
30. Newall AT. Understanding the cost-effectiveness of influenza vaccination in children: methodological choices and
seasonal variability. Pharmacoeconomics 2013;31(8):693-702.
31. Kelso JK, Halder N, Milne GL. Vaccination strategies for future influenza pandemics: a severity-based cost
effectiveness analysis. BMC Infect Dis 2013;13:81-5.
32. Skene KJ. A marginal benefit approach for vaccinating influenza “superspreaders”. Med Decis Making
2014;34(4):536-49.
33. Halder N, Kelso JK, Milne GJ. A model-based economic analysis of pre-pandemic influenza vaccination cost-
effectiveness. BMC Infectious Diseases 2014;14(1):266-70.
34. Zhou L. Cost-Effectiveness of Alternative Strategies for Annual Influenza Vaccination among
Children Aged 6 Months to 14 Years in Four Provinces in China. PLOS ONE 2014; 9(1):e87590.
35. Yamin D, Balicer RD, Galvani AP. Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.
Vaccine 2014;32(33):4198-205.
36. Gregg M. Economic evaluation of an influenza immunization strategy of healthy children. Int J Technol Assess
Health Care 2014;30(4):394-9.
37. Newall AT, Dehollain JP. The cost-effectiveness of influenza vaccination in elderly Australians: an exploratory
analysis of the vaccine efficacy required. Vaccine 2014;32(12):1323-5.
38. Yoo BK. Cost effectiveness analysis of Year 2 of an elementary school-located influenza vaccination program–
Results from a randomized controlled trial. BMC Health Services Research 2015;15:511-20.
39. Chit A. Expected cost effectiveness of highdose trivalent influenza vaccine in US seniors. Vaccine
2015;33(5):734-41.
40. Baguelin M. Extending the elderly- and riskgroup programme of vaccination against seasonal influenza in England
and Wales: a cost-effectiveness study. BMC Med 2015;13:236-40.
41. Lee BY. Quantifying the economic value and quality of life impact of earlier influenza vaccination. Med Care
2015;53(3):218-29.
42. Meeyai A. Seasonal Influenza Vaccination for Children in Thailand: A Cost-Effectiveness Analysis. PLOS Medicine
2015;12(5):e1001829.
43. Thorrington D, Jit M, Eames K. Targeted vaccination in healthy school children - Can primary school vaccination
alone control influenza? Vaccine 2015;33(41):5415-24.
44. Smith KJ. Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S. Am J Prev Med
2016;50(5):600-8.
45. Akin L. Cost-Effectiveness of Increasing Influenza Vaccination Coverage in Adults with Type 2 Diabetes in
Turkey. PLoS One 2016;11(6):e0157657.
46. Xu J. Cost-effectiveness of seasonal inactivated influenza vaccination among pregnant women. Vaccine
2016;34(27):3149-55.
47. Becker DL. High-dose inactivated influenza vaccine is associated with cost savings and better outcomes
compared to standard-dose inactivated influenza vaccine in Canadian seniors. Hum Vaccin Immunother
2016;12(12):3036-42.
48. Thorrington D. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England. BMC Med
2017;15(1):166-70.
49. Kittikraisak W. Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ?60
months of age. PLoS ONE 2017;12(8):e0183391.
50. Orenstein EW. Cost-effectiveness of maternal influenza immunization in Bamako, Mali: A decision analysis. PLoS
One 2017;12(2):e0171499.
51. Hodgson D. Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in
England and Wales: a modelling and cost-effectiveness analysis. The Lancet Public Health;2(2):e74-e81.
52. You, J.H., W.K. Ming, and P.K. Chan, Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent
influenza vaccine for elderly in Hong Kong. BMC Infect Dis, 2014.14:p. 618.
53. Blommaert A. Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and
persons with underlying illnesses in Belgium. Vaccine 2014; 32(46):6075-83.
54. Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent
influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One
2014;9(6):e98437.
55. Thommes EW. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention:
a dynamic modeling study of Canada and the United Kingdom. BMC Infectious Diseases 2015;15(1):465-70.
56. You JH, Ming WK, Chan PK. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision
analysis. Hum Vaccin Immunother 2015;11(3):564-71.
57. de Boer PT. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States. Value
Health 2016;19(8):964-75.
58. Dolk C. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based
Dynamic Transmission Model. Pharmacoeconomics 2016;34(12):1299-308.
59. Nagy L. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in
Finland. Pharmacoeconomics 2016;34:939-51.
60. Uhart M. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza
vaccines compared to trivalent influenza vaccines in Europe. Hum Vaccin Immunother 2016;12(9):2259-68.
61. Raviotta JM. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults. J
Am Geriatr Soc 2016;64(10):2126-31.